Pharsight

1. Ryzodeg 70/30 patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP02726984A		Genentech, Inc.	Patent maintained as amended
EP06701034A	2018-01-19	Schwöbel, Thilo	Opposition rejected
EP06754730A	2011-12-02	Ypsomed AG	Patent maintained as amended
EP06754730A	2011-11-30	WMC Matthes Consulting	Patent maintained as amended
EP06762643A	2010-07-30	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP05796880A	2010-07-14	Ypsomed AG	Granted and Under Opposition
EP05796880A	2010-07-14	Stöckeler, Ferdinand	Granted and Under Opposition
EP05796880A	2010-07-13	Ferring International Center S.A.	Granted and Under Opposition
EP05796880A	2010-07-13	OWEN MUMFORD LIMITED	Granted and Under Opposition
EP05796880A	2010-07-12	Genentech, Inc.	Granted and Under Opposition
EP05796880A	2010-07-12	COPERNICUS sp. zo.o.	Granted and Under Opposition
EP06121820A	2010-05-18	SANOFI-AVENTIS DEUTSCHLAND GMBH	Opposition rejected
EP02726984A	2006-03-01	TecPharma Licensing AG	Patent maintained as amended
EP02726984A	2006-02-23	OWEN MUMFORD LIMITED	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7615532	NOVO	Insulin derivatives	Jun, 2029 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866538	NOVO	Insulin preparations containing NaCl	Jun, 2017 (6 years ago)
US8672898	NOVO	Automatic injection device with reset feature	Jan, 2022 (2 years ago)
US6899699	NOVO	Automatic injection device with reset feature	Jan, 2022 (2 years ago)
US9486588	NOVO	Automatic injection device with reset feature	Jan, 2022 (2 years ago)
US8579869	NOVO	Needle mounting system and a method for mounting a needle assembly	Jun, 2023 (10 months ago)
US7762994	NOVO	Needle mounting system and a method for mounting a needle assembly	May, 2024 (20 days from now)
US8684969	NOVO	Injection device with torsion spring and rotatable display	Oct, 2025 (1 year, 5 months from now)
US9861757	NOVO	Injection device with an end of dose feedback mechanism	Jan, 2026 (1 year, 8 months from now)
US9616180	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (1 year, 8 months from now)
US9108002	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (1 year, 8 months from now)
US10376652	NOVO	Automatic injection device with a top release mechanism	Jan, 2026 (1 year, 8 months from now)
US10357616	NOVO	Injection device with an end of dose feedback mechanism	Jan, 2026 (1 year, 8 months from now)
US9775953	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jul, 2026 (2 years from now)
US10220155	NOVO	Syringe device with a dose limiting mechanism and an additional safety mechanism	Jul, 2026 (2 years from now)
US8920383	NOVO	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left	Jul, 2026 (2 years from now)
USRE46363	NOVO	Dial-down mechanism for wind-up pen	Aug, 2026 (2 years from now)
US7686786	NOVO	Dial-down mechanism for wind-up pen	Aug, 2026 (2 years from now)
US9687611	NOVO	Injection device with torsion spring and rotatable display	Feb, 2027 (2 years from now)
US9457154	NOVO	Injection device with an end of dose feedback mechanism	Sep, 2027 (3 years from now)
US9132239	NOVO	Dial-down mechanism for wind-up pen	Feb, 2032 (7 years from now)
US9884094	NOVO	Method of treating diabetes mellitus	May, 2033 (9 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Dec 16, 2019
New Chemical Entity Exclusivity(NCE)	Sep 25, 2020

NCE-1 date: 26 September, 2019

Market Authorisation Date: 25 September, 2015

Treatment: Method of improving glycemic control in patients with diabetes mellitus by administering a mixture of insulin degludec and insulin aspart during or around the time of the largest meal of the day

Dosage: SOLUTION;SUBCUTANEOUS

Pharsight

Drugs that contain Insulin Aspart; Insulin Degludec

1. Ryzodeg 70/30 patents expiration

RYZODEG 70/30 family patents

Related content